STOCK TITAN

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Novocure (NVCR) has appointed Christoph Brackmann as its next Chief Financial Officer. Brackmann will initially join as Senior Financial Advisor and transition to CFO on January 1, 2025, when current CFO Ashley Cordova becomes CEO. Brackmann joins from Moderna, where he served as Senior Vice President of Finance since 2019, leading the finance team during the COVID-19 pandemic. The 51-year-old executive previously held positions at Shire plc, Eli Lilly, and Novartis, bringing extensive experience in financial leadership and healthcare industry expertise.

Novocure (NVCR) ha nominato Christoph Brackmann come prossimo Direttore Finanziario. Brackmann entrerà inizialmente come Consigliere Finanziario Senior e passerà al ruolo di CFO il 1 gennaio 2025, quando l'attuale CFO Ashley Cordova diventerà CEO. Brackmann proviene da Moderna, dove ha ricoperto il ruolo di Vicepresidente Senior della Finanza dal 2019, guidando il team finanziario durante la pandemia di COVID-19. Il 51enne dirigente ha precedentemente ricoperto posizioni presso Shire plc, Eli Lilly e Novartis, portando con sé una vasta esperienza nella leadership finanziaria e una profonda conoscenza dell'industria sanitaria.

Novocure (NVCR) ha nombrado a Christoph Brackmann como su próximo Director Financiero. Brackmann se unirá inicialmente como Asesor Financiero Senior y hará la transición a CFO el 1 de enero de 2025, cuando la actual CFO Ashley Cordova se convierta en CEO. Brackmann proviene de Moderna, donde se desempeñó como Vicepresidente Senior de Finanzas desde 2019, liderando el equipo financiero durante la pandemia de COVID-19. El ejecutivo de 51 años ha ocupado previamente cargos en Shire plc, Eli Lilly y Novartis, aportando una amplia experiencia en liderazgo financiero y conocimiento en la industria de la salud.

Novocure (NVCR)는 Christoph Brackmann을 차기 최고 재무 책임자로 임명했습니다. Brackmann은 처음에 고위 재무 고문으로 합류하며, 2025년 1월 1일 현재 CFO인 Ashley Cordova가 CEO가 되는 시점에 CFO로 전환할 예정입니다. Brackmann은 Moderna에서 2019년부터 재무 수석 부사장으로 재직하며 COVID-19 팬데믹 동안 재무 팀을 이끌었습니다. 51세의 이 경영자는 Shire plc, Eli Lilly 및 Novartis에서 이전에 근무했으며, 재무 리더십과 의료 산업에 대한 폭넓은 경험을 가지고 있습니다.

Novocure (NVCR) a nommé Christoph Brackmann comme prochain Directeur Financier. Brackmann rejoindra initialement en tant que Conseiller Financier Senior et passera au poste de CFO le 1er janvier 2025, lorsque l'actuelle CFO Ashley Cordova deviendra PDG. Brackmann vient de Moderna, où il a occupé le poste de Vice-Président Senior des Finances depuis 2019, dirigeant l'équipe financière pendant la pandémie de COVID-19. Le dirigeant de 51 ans a précédemment occupé des postes chez Shire plc, Eli Lilly et Novartis, apportant une vaste expérience en leadership financier et une expertise dans l'industrie de la santé.

Novocure (NVCR) hat Christoph Brackmann zu seinem nächsten Chief Financial Officer ernannt. Brackmann wird zunächst als Senior Financial Advisor einsteigen und ab dem 1. Januar 2025 zum CFO wechseln, wenn die aktuelle CFO Ashley Cordova CEO wird. Brackmann kommt von Moderna, wo er seit 2019 als Senior Vice President of Finance tätig war und das Finanzteam während der COVID-19-Pandemie leitete. Der 51-jährige Executive hatte zuvor Positionen bei Shire plc, Eli Lilly und Novartis inne und bringt umfangreiche Erfahrung in finanzieller Führung und Fachkenntnis in der Gesundheitsbranche mit.

Positive
  • Strategic hire with extensive healthcare industry experience
  • Proven track record in managing financial operations during rapid company growth at Moderna
  • Planned smooth transition period with current CFO before assuming full role
Negative
  • None.

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO.

Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic.

“The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product portfolio and our global footprint,” said Ashley Cordova, Novocure’s current CFO and CEO succedent. “Christoph’s knowledge of our industry, strategic insight and experience leading successful financial organizations through periods of growth will be valuable assets to Novocure. I look forward to partnering with him as we work to deliver on our commitments in the coming years.”

“Novocure is founded on an innovative idea that has been developed into multiple products that changed how cancer is treated. The potential of this organization is energizing, especially as it is poised to expand into new indications,” said Mr. Brackmann. “I am eager to contribute to the organization’s patient-forward mission and to work with this team to drive Novocure to reach its full potential for patients, employees and our shareholders.”

During his career at Moderna, Mr. Brackmann, 51, oversaw the expansion and development of the Finance function, including Financial Planning and Analysis, Accounting, Tax, Treasury, Procurement and Business Services. Prior to Moderna, Mr. Brackmann served as the Vice President of Investor Relations and Head of International Finance at Shire plc (acquired by Takeda), and in various financial roles at Eli Lilly and Company and Novartis. Mr. Brackmann earned his Master of Business Administration from the SDA Bocconi School of Management, Milan and holds a bachelor’s degree in Business and Economics from the University of Mannheim.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Root Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “could” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors:

Ingrid Goldberg

investorinfo@novocure.com

Media:

Catherine Falcetti

media@novocure.com

Source: Novocure

FAQ

When will Christoph Brackmann become CFO of Novocure (NVCR)?

Christoph Brackmann will transition to the role of CFO at Novocure on January 1, 2025.

What is Christoph Brackmann's current role at Novocure (NVCR)?

Brackmann is currently joining Novocure as a Senior Financial Advisor before transitioning to CFO.

Where did Novocure's new CFO Christoph Brackmann work before?

Before joining Novocure, Brackmann served as Senior Vice President of Finance at Moderna since 2019, and previously held positions at Shire plc, Eli Lilly, and Novartis.

Why is Novocure (NVCR) appointing a new CFO?

Novocure is appointing a new CFO because current CFO Ashley Cordova will become CEO on January 1, 2025.

NovoCure Limited Ordinary Shares

NASDAQ:NVCR

NVCR Rankings

NVCR Latest News

NVCR Stock Data

1.88B
97.93M
9.26%
86.65%
5.5%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ST. HELIER